ICON Public Company (ICLR) investor relations material

Executive summary

• Q2 2026 revenue reached $2,063.5 million, up 1.4% sequentially and 1.2% year-over-year, with adjusted EBITDA margin at 15.9% and adjusted EPS of $2.56; net business wins totaled $3,120 million (1.51x book-to-bill), reflecting strong demand and disciplined cost management.

• Notable growth in biotech RFP flow, balanced award profile, and ongoing cross-selling initiatives supported performance, especially in phase III opportunities.

• Strategic investments in AI, technology, and Asia-Pacific capabilities, including partnerships with Anthropic, Microsoft, and a new China partnership, are supporting long-term growth.

• CEO reaffirmed full-year 2026 guidance, reflecting balanced opportunities and risks for H2.

Financial highlights

• Q2 2026 revenue was $2,063.5 million, up from $2,034 million in Q1 2026 and $2,039 million in Q2 2025, driven by higher pass-through activity.

• Adjusted EBITDA was $327.2 million (15.9% margin), up 3% sequentially but down from 20.5% in Q2 2025.

• Adjusted EPS was $2.56, down from $3.52 in Q2 2025 but up from $2.50 in Q1 2026.

• Adjusted net income was $198.4 million; GAAP net income was $72.6 million ($0.94 per diluted share).

• Free cash flow for Q2 was $238.9 million; cash at quarter-end was $928.4 million, with net debt at $2.5 billion and leverage ratio at 1.8x.

Outlook and guidance

• Full-year 2026 revenue guidance is $7,850–$8,150 million, with adjusted EPS expected between $10.00 and $11.00.

• Guidance excludes future share repurchases and M&A activity; capital expenditure projected at approximately $200 million.

• EBITDA margin for the year expected around 16.5% at midpoint, potentially trending lower if pass-throughs remain high.

• Sequential EBITDA dollar improvement targeted for H2, driven by gross margin expansion and cost actions.

• Direct fee revenue expected to decline ~2% year-over-year, with inorganic drag from Symphony divestment.